Category - Developments

Developments

Titan Pharma receives positive EU CHMP opinion for Probuphine (“Sixmo”)

Titan Pharmaceuticals (NASDAQ:TTNP) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for marketing authorization of Sixmo, the brand name for...

April 29, 2019

Developments

Canopy Growth secures site for NY state hemp industrial park

Canopy Growth (TSX:WEED; NYSE:CGC) secured a 308,000-square-foot facility on a 48-acre property in Kirkwood, NY for its hemp industrial park in the southern tier region of New York State. The vision for the property is...

April 29, 2019

Developments

Titan Pharma’s Probuphine implant to treat OUD continues to gain national media attention

Channel 8’s Daytime aired nationally an interview with two senior executives of Titan Pharmaceuticals (NASDAQ:TTNP) – Dane Hallberg, EVP and chief commercial officer, and Dr. Kate DeVarney, EVP and chief scientific...

April 26, 2019

Developments

Orchard Therapeutics doses first patient in cryopreserved gene therapy trial

Orchard Therapeutics (NASDAQ:ORTX) has dosed the first patient in a study evaluating a cryopreserved formulation of OTL-103, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of Wiskott...

April 25, 2019

Developments

Kane Biotech in sales representation pact with SLA Brands

Kane Biotech (TSXV:KNE) entered a strategic partnership with Schiaffino, Lasky, & Associates (SLA Brands) to exclusively represent Kane’s bluestem line of products to distributors and retailers in the U.S. market...

April 24, 2019

Developments

Akari reports positive initial results from Phase 2 bullous pemphigoid trial

Akari Therapeutics (NASDAQ:AKTX) reported positive results from the first three bullous pemphigoid (BP) patients in an ongoing Phase 2 clinical trial. BP is a severe orphan inflammatory skin disease characterized by...

April 23, 2019

Developments

Researchers develop potentially safer CAR-T treatment

Researchers at the University of Southern California’s (USC) Norris Comprehensive Cancer Center have designed a new type of CAR-T treatment that reduces the risk of cytokine release syndrome (CRS), a dangerous immune...

April 23, 2019

Developments

Alder BioPharma BLA for eptinezumab accepted by FDA

Alder BioPharma (NASDAQ:ALDR) BLA application for eptinezumab, a monoclonal antibody for the prevention of migraines, has been accepted by the FDA. Administered intravenously, eptinezumab targets and suppresses...

April 23, 2019

Developments

Autolus Therapeutics ALL treatment gets FDA orphan drug designation

Autolus Therapeutics’ (NASDAQ:AUTL) AUTO3 has received FDA orphan drug designation for the treatment of acute lymphoblastic leukemia (ALL). AUTO3 is a T-cell therapy produced by genetically modifying a patient’s own T...

April 23, 2019

Developments

Sensus Healthcare SRT shows 98.9% skin cancer cure rate in retrospective study

Sensus Healthcare’s (NASDAQ:SRTS) superficial radiation therapy (SRT) demonstrated a 98.9% skin cancer cure in a five-year retrospective study. Sensus’ SRT is a low-energy X-ray technology used to treat non-melanoma...

April 23, 2019

Category - Developments

Titan Pharma receives positive EU CHMP opinion for Probuphine (“Sixmo”)

Canopy Growth secures site for NY state hemp industrial park

Titan Pharma’s Probuphine implant to treat OUD continues to gain national media attention

Orchard Therapeutics doses first patient in cryopreserved gene therapy trial

Kane Biotech in sales representation pact with SLA Brands

Akari reports positive initial results from Phase 2 bullous pemphigoid trial

Researchers develop potentially safer CAR-T treatment

Alder BioPharma BLA for eptinezumab accepted by FDA

Autolus Therapeutics ALL treatment gets FDA orphan drug designation

Sensus Healthcare SRT shows 98.9% skin cancer cure rate in retrospective study

General

More